Abstract 1455: "Tasimelteon improves symptoms of major depression in an African American population."
Abstract 1539: "Tasimelteon improves sleep quality and behavior in individuals with Smith-Magenis syndrome (SMS) in an open-label study."
Abstract 1543: "Differences in the timing of melatonin secretion between African American and Caucasian patients with major depressive disorder."
Abstract 1454: "Estimating burden of disease among blind individuals with non 24 hour sleep wake disorder."
For more information on World Sleep 2017, please refer to http://worldsleepcongress.com/
About Vanda
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on
Corporate Contact:
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
View original content:http://www.prnewswire.com/news-releases/vanda-to-present-scientific-posters-at-world-sleep-2017-300528391.html
SOURCE